Kura Oncology Reports $13.9 Million in Product Revenue in Third Quarter
Key Facts
Kura Oncology reported third-quarter results on November 10, 2026, recording net product revenue of $13.9 million, up 53% from the second quarter, according to the company statement. That revenue puts commercial drug KOMZIFTI at the forefront of the period’s developments, with new treatment starts and prescriptions increasing. By contrast, collaboration revenue fell from the same quarter last year, limiting the impact of product sales growth on total revenue. The statement did not include market estimates that would show whether earnings per share or revenue exceeded analysts’ expectations. The reported results therefore focus on actual operating and financial figures and comparisons with prior periods.
The company’s total revenue was $22.839 million in the third quarter of 2026, compared with $20.750 million in the same period of 2025, according to the statement. The total comprised $13.9 million in net product revenue and $8.9 million in collaboration revenue. Collaboration revenue was $20.8 million in the third quarter of 2025, underscoring the year-over-year decline in that source as product sales began contributing to results. On a quarterly basis, net product revenue rose 53% from the second quarter of 2026. The divergence between the two sources reflects a shift in the revenue mix during the period, with the commercial product growing and annual collaboration revenue falling.
Chief Executive Troy Wilson said KOMZIFTI revenue grew 53% quarter over quarter and new treatment starts rose 30%, with the drug continuing to hold the largest share of treatment starts in the menin inhibitor class. About 150 new patients started treatment during the quarter, up 30% from the second quarter of 2026. Total prescriptions also exceeded 420, including repeat prescriptions, rising 65% from the previous quarter. These indicators provide detail on the drug’s expanding commercial use during the period, alongside revenue growth. The U.S. Food and Drug Administration approved KOMZIFTI on November 13, 2025, to treat adults with relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation when no satisfactory alternative treatment options are available.
On expenses, the company recorded $66.9 million in research and development expenses in the third quarter, compared with $67.9 million a year earlier. Selling, general and administrative expenses were $30.2 million, versus $32.8 million in the third quarter of 2025, according to the earnings statement. Although both items declined from their year-earlier levels, the company recorded a net loss for the quarter, and the statement did not provide analyst estimates for comparison. The published results included actual revenue and expenses, while the figures provided do not offer a basis for verifying the earnings-per-share surprise cited in the initial account of the news. The available comparison is therefore limited to the reported financial performance and the prior periods identified by the company.
Cash, cash equivalents and short-term investments totaled $492.1 million on September 30, 2026, compared with $667.2 million on December 31, 2025, according to the company. The September-end balance comes as the company funds operations and develops its programs, while KOMZIFTI continues to build commercial revenue and other programs advance toward upcoming clinical milestones. Kura expects its resources to fund operations beyond the anticipated 2028 initial results from the pivotal Phase 3 KOMET-017 study. The company did not specify a date beyond those results in this forecast, linking the sufficiency of its resources to the expected study milestone. This places the reported cash balance alongside the timeline for its main clinical program.
Kura updated its 2026 collaboration revenue guidance to a range of $40 million to $45 million, while maintaining its forecast of revenue between $90 million and $110 million in each of 2027 and 2028. The company said the guidance reflects non-cash accounting recognition and does not specify the timing of cash receipts, a distinction relevant when considering the estimates alongside the cash balance. In development, it aims to start a single-arm registration study of about 40 patients with HRAS-mutant salivary gland cancer in the first half of 2027, after reaching agreement with the U.S. Food and Drug Administration on the study design. It also aims to complete enrollment in the randomized Phase 1b portion of the FIT-001 study in the first half of 2027 and announce initial clinical data in the second half of that year. These are the company’s stated milestones for its upcoming programs.
For KOMZIFTI, Kura said eight drug-related abstracts were accepted for the American Society of Hematology annual meeting in New Orleans from December 12 to 15, 2026, including four oral presentations and four posters. The FDA’s approval of the drug was based on the open-label KO-MEN-001 trial, which included 112 adults with relapsed or refractory acute myeloid leukemia with an NPM1 mutation. The company’s chief medical officer, Molly Leoni, said the first clinical results for the drug’s combinations with FLT3 inhibitors “expand this strategy to include combinations with FLT3 inhibitors.” The company said FLT3 mutations occur in nearly one-third of patients with acute myeloid leukemia and about half of patients with an NPM1 mutation. Kura scheduled an update call on the society meeting for December 15, 2026, at 8:30 a.m. Eastern time.